Genzyme planning to buy back marketing rights to Synvisc

November 08 2004

Genzyme plans to buy back the sales and marketing rights to the osteoarthritis pain drug Synvisc from Wyeth. The transaction is ...

Your Name: *

Your Email Address: *

Recipient(s) Email Address: *

(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)

Subject:*

Your message:

Send Me A Copy

The e-mail address(es) that you supply to use this service will only be used to send the requested article.